Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.
about
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIVAbacavir-based triple nucleoside regimens for maintenance therapy in patients with HIVAbacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSubstituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentDetermination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function.Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTIChanging patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Switching effective antiretroviral therapy: a review.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeAntiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations.Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapyOnce-daily therapy: less is more.Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.Practical discussion on switching studies and how this relates to managing lipids.Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents.Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor.A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results.Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 monthsGuidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the
P2860
Q24202180-6D540CC0-A347-45FA-8155-1B7442AC2F79Q24239828-00BEB8B8-8CB9-4948-B463-9D3C157B886FQ24799351-D803AC1F-CB79-4DF9-B974-75517CE50FD2Q24803596-F8BC02BF-9268-4519-BF68-36C9737CBEFDQ33207117-B923749C-CE3C-47EE-80E9-259166625B5BQ33378805-1580E607-1CFD-4CB7-B6E3-D39947482EF6Q33803473-9C62E16D-9E72-43C0-9777-DE313D774355Q34414078-2F707F96-F2EA-466D-9A76-C22590530DE3Q34985833-826341EF-0BC6-4CC4-8FE1-82D24917A116Q35124959-1ADF1CC6-BDBC-437D-A936-6B1B3A9CE9A0Q35129194-D5D099D1-411E-4EC9-B00B-A0318A4C9B3AQ35158051-2F31660F-4050-41E5-A10E-C821963BE128Q35583692-1178C3FF-9D1B-4A29-B4F5-72BF23986311Q35805765-8E1D1033-CFF9-4CF8-9A97-DF2A6858CC5EQ36292308-FD2E993C-53E2-4F29-8504-CAE78F98964DQ36322100-E875A7C8-1923-42CD-A6B7-C5F30BA704F7Q36632128-0FE1BB0C-CA3D-42AA-B1AB-061EE3C5CCB7Q36739802-5B18CA06-B1DF-49E4-A491-7B396287C1DBQ37154669-F46258DE-8CA9-4563-A390-0515B5CA32E2Q37399199-8D46041B-6EA8-4D92-B7D6-026CF29755BAQ38346020-1490CFCD-2A7D-4738-AE18-E1A01D722138Q39652630-53BF0420-D862-4C88-B099-792D2DCF0D79Q41619728-677D89C0-4A1F-43AB-8A90-B5FA60D5630DQ44408004-12F55F88-0AAA-49E7-B8A2-8F4F29787734Q44657176-40C486D5-E873-44DD-A19E-1CEE474427C3Q46474207-A653FFA1-08DB-4ED7-9146-2FE145D880BFQ46899234-C920BBB1-89C1-4F3E-A686-D750391E850CQ46935128-6DF7F623-63F0-4105-8E75-5C62788DAB28Q57609598-51FD8FF5-9B41-4071-A1F5-BD04D5AA1ADCQ58375437-1BD15B93-0D5F-4666-8C53-A4F073F0611E
P2860
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Simplification with abacavir-b ...... undetectable plasma HIV-1 RNA.
@en
Simplification with abacavir-b ...... undetectable plasma HIV-1 RNA.
@nl
type
label
Simplification with abacavir-b ...... undetectable plasma HIV-1 RNA.
@en
Simplification with abacavir-b ...... undetectable plasma HIV-1 RNA.
@nl
prefLabel
Simplification with abacavir-b ...... undetectable plasma HIV-1 RNA.
@en
Simplification with abacavir-b ...... undetectable plasma HIV-1 RNA.
@nl
P2093
P1433
P1476
Simplification with abacavir-b ...... undetectable plasma HIV-1 RNA.
@en
P2093
CNA30017 Study Team
J Gerstoft
J Montaner
R Athisegaran
P304
P356
10.1097/00002030-200108170-00009
P407
P577
2001-08-01T00:00:00Z